Tatiana Popkova

TL;DR: Examination of lipid profiles, arterial stiffness, carotid intima-media thickness, and cIMT in 55 women with RA without overt cardiovascular disease treated with rituximab (RTX) found improvement of cardiovascular parameters was accompanied by statistically significant decreases of CRP, ESR, RF IgM and DAS 28.

TL;DR: Differences in the prevalence of both CVD and major CVD risk factors were observed across the four regions investigated, and may contribute to heterogeneity on the observed safety of investigational and approved therapies in studies involving RA patients from different origins.

TL;DR: It is demonstrated that increase and phenotypic changes in Treg population correlate well with response to methotrexate treatment, and the role of Tregs as specific cellular marker of successful RA treatment is speculated.

TL;DR: Tofacitinib (TOFA) is an oral reversible inhibitor of janus kinases for the treatment of RA with proven efficacy and good tolerability, but its effects on body weight and metabolic profile need to be clarified.

TL;DR: The patients with early-stage RA were found to have high incidence rates of LVDD and RVDD, which is related to the high prevalence of CVD, the high spread of TRF for CVD and the high activity of an inflammatory process.